{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"A confirmed response is defined as a patient who has achieved response and maintained it on two consecutive evaluations at least 2 weeks apart.\n\nA Complete Response (CR) is defined as the complete disappearance of an M-protein and fewer than 5% bone marrow plasmacytosis.\n\nA Hematologic Very good partial response (VGPR) is defined as having a ≥ 90% reduction of M-protein from serum, a Urine M-spike to be ≤ 100 mg/24 hours, and a disappearance of soft tissue plasmacytomas.\n\nA Partial Response (PR) is defined as having a 50-89% reduction in the level of the serum monoclonal protein, a reduction in 24-hour urinary light chain excretion either by ≥90% or to \\<200 mg, and a ≥ 50% reduction in size of soft tissue plasmacytoma.","groups":[{"description":"Patients receive oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Kinase Inhibitor Therapy)"}],"paramType":"NUMBER","populationDescription":"All 13 participants were evaluable for a response","reportingStatus":"POSTED","timeFrame":"Every 6 weeks from the first initiation of therapy up to 72 weeks","title":"The Number of Confirmed Responses (Complete Response [CR], Very Good Partial Response [VGPR], or Partial Response [PR])","type":"PRIMARY","unitOfMeasure":"participants"}